Table 1.
Clinical characteristics of ER-positive patients with fulvestrant usage (n = 135)
| Covariate level | All patients (n = 135) | Fulvestrant usage | p value | |
|---|---|---|---|---|
| first line (n = 116) | ≥second line (n = 19) | |||
| Age at diagnosis, years | 53 (27–82) | 53 (27–82) | 52 (30–71) | 0.792 |
| Age at fulvestrant usage, median years | 57 (30–67) | 57 (30–67) | 55 (35–52) | 0.620 |
| ER, n (%) | ||||
| Negative | 14 (10.37) | 12 (10.34) | 2 (10.5) | 0.977 |
| Positive | 121 (89.63) | 104 (89.65) | 17 (89.5) | |
| PR, n (%) | ||||
| Negative | 27 (20.00) | 22 (18.97) | 5 (26.32) | 0.438 |
| Positive | 108 (80.00) | 94 (81.03) | 14 (73.68) | |
| HER2, n (%) | ||||
| Negative | 108 (80.00) | 91 (78.44) | 17 (86.47) | 0.538 |
| Positive | 14 (10.37) | 13 (11.20) | 1 (5.26) | |
| Unknown | 13 (9.63) | 12 (9.48) | 1 (5.26) | |
| Histological grade, n (%) | ||||
| I | 15 (11.11) | 12 (10.34) | 3 (15.79) | 0.080 |
| II | 68 (50.37) | 56 (48.28) | 12 (63.16) | |
| III | 52 (38.52) | 48 (41.38) | 4 (21.05) | |
| Stage, n (%) | ||||
| I | 21 (15.55) | 20 (17.44) | 1 (5.26) | 0.205 |
| II | 49 (36.30) | 39 (33.85) | 10 (52.63) | |
| III | 53 (39.26) | 45 (38.79) | 8 (42.11) | |
| IV | 12 (8.89) | 12 (10.34) | 0 (0) | |
| Metastatic sites, n (%) | ||||
| Lymph nodes | 43 (31.85) | 40 (34.88) | 3 (15.79) | 0.364 |
| Bone | 80 (59.26) | 68 (58.62) | 12 (63.12) | |
| Visceral | 69 (51.11) | 62 (53.44) | 7 (36.84) | |